2020 Annual Business Report

A specialty
vaccine company

img-small

CEO statement

“2020 has been a transformational year for Valneva”

Thomas Lingelbach President & CEO of Valneva

TOTAL
revenues 2020

110.3m
Our employees

Our employees

Valneva’s success stems from the dedication and expertise of approximately 580 employees spanning the whole value chain, from R&D to commercialization.

2020  Highlights

2020 Highlights

In 2020, Valneva achieved several major milestones, further enhancing its unique value proposition.

Our strategy

Our strategy

Valneva aims to build a leading vaccines company with a portfolio of specialized assets targeting diseases with limited preventive or therapeutic treatment options.

 

Frédéric Jacotot General Counsel and Corporate Secretary

Valneva's Management Board Our Corporate Governance Approach

Our Corporate Governance Approach

Our commitment to Corporate Governance underpins the trust that our investors, employees and institutions have placed in us.

Corporate Social Responsibility

Corporate Social Responsibility

Valneva has defined long-term responsible business commitments, which reflect global health needs and sit across four key focus areas. Our four pillars are the foundation for our Corporate Social Responsibility approach.